Innovation meets cardiovascular trial expertise.
Cardiovascular clinical trials, no matter their size, demand a specialized, experienced cardiovascular CRO to help you navigate the path to success. With unmatched cardiovascular trial experience and new approaches fueled by data and analytics, BioFicher brings agility and speed to trials large and small.
Clinical Experience
BioFicher has contributed to the advancement of Cardiovascular knowledge through participation in hundreds of global studies ranging from the most common tumor types to the rarest of cancers. In collaboration with biopharmaceutical companies and government, we confront the challenges of recruiting from small or geographically sparse patient populations and managing trials that are complex for investigative sites with innovative oncology solutions. Our unique expertise in adaptive/alternative study designs and biostatistics and oncology market research enables us to mitigate some of those challenges for our clients.
169
Studies Conducted
22,612+
Patients Involved
1800+
Site Worldwide
Drive smarter decisions for your cardiovascular trial
.jpg)
Below is a summary of everything we can do to help ensure medical devices for sale in the EU conform to all requirements:
-
Reduce patient burden with Decentralized and Hybrid trial solutions
-
Model and predict event rates with the world’s largest healthcare data source
-
Optimize study protocols by refining eligibility criteria and schedule of assessments
-
Create Direct-to-patient multi-channel recruitment campaigns for rare and common disease populations
-
Enable patient-centered recruitment and tailored site strategies through new technology solutions
-
Monitor safety and efficacy endpoints in near real time with wearables and connected devices
BioFicher's experienced cardio-metabolic drug and medical device development teams support clinical trials across multiple indications, including:
.jpg)
Unique Experience
With a focus on chemotherapies and biologics, BioFicher has contributed to a number of groundbreaking studies including the following:
-
The first peptide to be used in melanoma vaccines
-
Studies with patient populations that have co-morbid conditions like HIV
-
Individualized immunotherapy including CAR-T
-
Gene sequencing in MDS
Challenges of cardiovascular development
-
Pressure to bring down the time and cost of cardiovascular trials
-
Need for fast site activation and recruitment of extremely large patient populations globally
-
Retention of patients to prevent lost to follow-up (LTFU) over the length of the study
-
Analysis of vast amounts of data quickly to detect safety signals and endpoint information
Research with a Purpose
Connected approach to your cardiovascular trials Through our Connected Intelligence approach to cardiovascular development, BioFicher can help you rethink old challenges and surround your trials with a proven suite of capabilities to help you reach milestones faster, deliver programs within budget, and bring game-changing therapies to patients sooner.
Cardiovascular Leaders
At BioFicher Sciences, we value the open exchange of communication between our therapeutic area leaders and your team. We encourage you to contact us to discuss your research plan and determine how we can support your development pathway.
Traci Clemons, Ph.D.
Chief Research Officer
Traci Clemons, Ph.D.
Director and Biostatistician, Ophthalmic Therapeutic and Research Unit